Safety and Efficacy of Combination of Niraparib in The Treatment of Advanced Breast Cancer: A Case Report

1. Abstract
BRCA is a common susceptibility gene for breast cancer, PARP inhibitors are target drugs for BRCA mutation. The most of clinical trails and case reports of PARP inhibitors are monotherapy. Rare focus on the combination of other therapies. We herein report the first case of a breast cancer patient who underwent the combination of Niraparib with chemotherapy and the combination of Niraparib with endocrine therapy and Immunotherapy in the hope of bringing new views to the clinical application of PARP inhibitors.